ARTICLE | Company News

Astellas gains rights to Chromocell pain program

October 1, 2015 1:02 AM UTC

Astellas Pharma Inc. (Tokyo:4503) gained exclusive, worldwide rights to commercialize CC8464 and backup candidates from Chromocell Corp. (North Brunswick, N.J.) in pain indications.

Chromocell plans to submit an IND for CC8464 in early 2016. The company plans to lead development of the oral, peripherally acting Nav1.7 antagonist through a Phase IIa proof-of-concept trial in neuropathic pain. Astellas is to lead all further development in the indication. ...